Home
/
OptimizeRx Corp
/
Financials
/
Quarterly
OptimizeRx Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that OptimizeRx Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$26.07M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$29.20M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$21.93M
May 13, 2025
Q3
2025
Sep 30, 2024
$21.31M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$18.81M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$19.69M
May 13, 2025
Q3
2024
Sep 30, 2023
$16.33M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$13.82M
Aug 15, 2024
Q1
2024
Mar 31, 2023
$13.00M
May 15, 2024
Q3
2023
Sep 30, 2022
$15.09M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$13.98M
Aug 14, 2023
Q1
2023
Mar 31, 2022
$13.73M
May 12, 2023
Q3
2022
Sep 30, 2021
$16.12M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$13.63M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$11.23M
May 9, 2022
Q3
2021
Sep 30, 2020
$10.52M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$8.78M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$7.58M
May 6, 2021
Q3
2020
Sep 30, 2019
$5.00M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$7.01M
Aug 5, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$2.78M
May 2, 2018
Q1
2018
Mar 31, 2017
$1.40M
May 2, 2018
Q3
2013
Sep 30, 2013
$1.37M
Nov 14, 2013
Q2
2013
Jun 30, 2013
$1.10M
Aug 12, 2013
Q1
2013
Mar 31, 2013
$669.3K
May 15, 2013
Q3
2013
Sep 30, 2012
$453.2K
Nov 14, 2013
Q2
2013
Jun 30, 2012
$515.4K
Aug 12, 2013
Q1
2013
Mar 31, 2012
$329.4K
May 15, 2013
Q3
2012
Sep 30, 2011
$191.6K
Nov 14, 2012
Q2
2012
Jun 30, 2011
$200.2K
Aug 14, 2012
Q1
2012
Mar 31, 2011
$393.8K
May 15, 2012
Q3
2011
Sep 30, 2010
$40.7K
Nov 23, 2011
Q2
2011
Jun 30, 2010
$16.7K
Aug 17, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$779.0K
Nov 7, 2025
Q2
2025
Jun 30, 2025
$1.53M
Aug 8, 2025
Q3
2025
Jun 30, 2025
$1.53M
Nov 7, 2025
Q2
2025
Mar 31, 2025
($2.20M)
Aug 8, 2025
Q3
2025
Mar 31, 2025
($2.20M)
Nov 7, 2025
Q1
2025
Mar 31, 2025
($2.20M)
May 13, 2025
Q3
2025
Sep 30, 2024
($9.12M)
Nov 7, 2025
Q3
2025
Jun 30, 2024
($4.01M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($4.01M)
Aug 8, 2025
Q3
2025
Mar 31, 2024
($6.90M)
Nov 7, 2025
Q2
2025
Mar 31, 2024
($6.90M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($6.90M)
May 13, 2025
Q3
2024
Sep 30, 2023
($2.87M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($4.16M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($4.16M)
Aug 15, 2024
Q2
2024
Mar 31, 2023
($6.40M)
Aug 15, 2024
Q3
2024
Mar 31, 2023
($6.40M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($6.40M)
May 15, 2024
Q3
2023
Sep 30, 2022
($3.47M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($3.88M)
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.05M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$3.19M
Aug 8, 2025
Q1
2025
Mar 31, 2025
($2.11M)
May 13, 2025
Q3
2025
Sep 30, 2024
($8.56M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($3.75M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($5.03M)
May 13, 2025
Q3
2024
Sep 30, 2023
($3.55M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($4.85M)
Aug 15, 2024
Q1
2024
Mar 31, 2023
($7.06M)
May 15, 2024
Q3
2023
Sep 30, 2022
($3.76M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($3.91M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($3.76M)
May 12, 2023
Q3
2022
Sep 30, 2021
$38.2K
Nov 8, 2022
Q2
2022
Jun 30, 2021
$340.1K
Aug 9, 2022
Q1
2022
Mar 31, 2021
($638.3K)
May 9, 2022
Q3
2021
Sep 30, 2020
($176.7K)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($1.06M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($2.26M)
May 6, 2021
Q3
2020
Sep 30, 2019
($1.99M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
$480.0K
Aug 5, 2020